our the confidence Thank you significant since cortical call you, Lisa this last and for program progress thank grow. afternoon. creating made investor stimulation our with artificial Orion vision our call all We to in continues via and joining
Before QX reviewing the the business. of Argus review disappointing last Argus will we QX We II of held our investor was This let's details momentum exciting implants million completed when XX details quarter we the more happened what given Orion, during in the experiencing call. in with John $X.X revenue. were later. resulting in provide
to also reimbursement CMS outpatient were rate U.S. CMS payment for of for procedures in coming for this will forward devices year. to provide ruling will low look a in that XXXX extremely were to the We the feel four this and approximately CMS associated We stability $XXX,XXX surgical the such on volume the methodology Argus and Argus. comments as volume setting up by more provide propose July to average pleased low Medicare considers XX. On preliminary a methodology new for reimbursement devices years with and proposed later of rate we new procedure see for we rates months front, happy final data the
I will data of vision expansion this with the point, in believe We label clinical additional be RP continue required the by label. to support FDA a At dialogue to our to have patients. a concerning the better U.S. agency the expansion include
clinical now totals database cleared flat coordinator our basically patients, patient which from XXX is U.S. last Our update.
qualified of candidates focus to funnel. our moving excited and We XXXX this continue for to database remainder be the about changed through recently the
in from our In database. implanted QX during U.S. patients X the fact, of were X
quarter. II-S, Argus named testing this Finally, externals, our next gen start should validating clinical
II-S Argus CPU camera. the and new reminder, features including a eyewear, a new a As
end addition schedule. and to those we and Argus Argus users, implanting on feasibility I'd we study procedure, enrollment go our inspire completing the with much more amongst year. We update in pleasing. completed be you II-S with to of At being II-S our believe designed ahead is centers when filings regulatory fifth clinical Argus ahead and subsequent upgradable clinical After the to a proceed database. comfortable our patients with and met currently Orion. the with enthusiasm like this weighing be potentially platform, they locations, now and will several of in launch with the aesthetically May, expect U.S. In later to validation initial the powerful subject including more progress patients should work at validation
teams UCLA You'll soon. we at to at of implanted in from expect with Los we to Houston we enroll subject recall screening five X were the Baylor FDA and subjects sixth subjects. Angeles implant Baylor approval Since subject implanted in UCLA, submitted and a working be Baylor. the our test were to received request actively is and a at and subjects Xth that
this technology We efficacy I subjects evaluate their safety breakthrough and are of clinical to are participation All this trial. very diligently data enthusiastic technology. and gathering about the
input over of include subjects by very using system from over cleared The being without are maps seeing use, various stages generally home Observations subjects X and they of on spatial parameters start X the and ranges supervision. and the for maps testing Spatial to progressed are to early within electrodes. generally subjects. time. at virtually stable have One close expected and following. devices have subject home Stimulation our vary can all the first meaning stable time. of video The real-time are five out subject all report with their for is using spots activated light we creation at is
identify between activated. when As of a established in is reminder, testing, spatial light than test the electrode Argus. direction screen. are spot this their visual of appears undergoing the field larger results are to a on very directional of encouraging. Early field lines subject subjects various where In be motion relationship the maps motion Several that electrodes of The view a and sees computer subjects testing.
has reliability been performance. device device Finally, has good as
to experienced SAE. from we seizure one algorithm. and adverse safety an subjects our as and the when top serious adverse and the while in clinical experienced the after implanting was participating One resolved front, a have for priority On the by continue study the Seizures our the safety were The the continue in each committee subject closely. we and in committee stimulation subject study was institution. at protocol clinic video event is without clinic was the allowed to or released seizure subject event, listed specific event are a we of reviewed subject for the quickly a the a evaluating safety monitor need hospitalization. anticipated The will
and start appropriate. their daily a their first soon our to with look to coming the gather understanding home. interpret from rehabilitation will Orion and use In we updates in the I Looking is forward deploying representatives benefits work as educate forward, in much U.S. system. subjects This on in to the vision Orion ultimately and begin gen potential data life. system the providing provide team what the we more months, we of vision critical with the can level optimize around order will subjects to to step how
the nicely. discussions Our FDA proceeding are with
program, As breakthrough is device to discussed Orion pathway calls, in program. also expedited referred the part as past of the access
feedback responses. FDA the very with interactions have been productive with or timely Our
market more upcoming firm U.S. expected the and us engaged We the pathway the details help assess as will Orion. year, a we increases. party calls certainty commercialization provide our clinical to on potential timeline regulatory around Last in third for
technology the approximately we or estimates the multibillion U.S. XXs, the include our XXX,XXX by could As The light in robust individuals given are potentially expected, Based research estimates Orion over to for advanced lives. legally third bare of better the market and market treatable nerve our the glaucoma, there dollar could party data from population a younger, market significantly over whose also with Argus, vision loss this label. of the older than trauma. U.S. treat of bare eye perception younger additional eye conducting that as or no with is II average on expand with patients be actual research, and course the in indicating a the individuals their would XX,XXX gained market U.S. of validated The Orion this with These experiencing with potentially the that the impacted more worse. lifespan, insights the patients. criteria Moreover, our only appears diabetic individuals disease, published the current addressable this vision Prior as progressed who than does pricing to X,XXX population. had medical in limit from U.S. population The assumptions, patients data utilizing of believe and is an could three light by Those are the trauma population. market a research at market. tend larger vision the age treated stage and their market the the eligibility segment is for of been the of Orion had regions conservative five to number no largest of analysis, patient be market the populations to population we Orion and to process conditions to estimates, on RP world. the In U.S. the U.S. research blind trauma believe some represent times opportunity. other to their also benefit retinopathy, due potential not patients research, expanding RP RP with research defined valuable optic suggests who opportunity our in in the perception. be that Again, generally light case Argus not in may a many market these this label
but some These are I'd believe efforts with important may are very some exciting conjunction research we become as research internally in in like treating in the partners. populations. to some cases, still Next, highlight or we large start we phase, conducting patient research projects
to is enables with created. eyes with and when the This Orion. a field technology important objects helping Argus the your of brain efforts user's Argus If and implant not, is develop eyes. but improving the with integrate thus movement This eyes in user's minimize this technology the a advanced or of the the does visual us location move. move stability technology distortion to see eventually, eye a the in partner have from by the we the distortion First, the view implement expects quality tracking would of conjunction and the better move to view provided. information, our brain This eliminate vision camera relative different because
could and integrate with salient option allow another especially imaging are in with a we people to users in provide visualize and room, warm technology thermal working objects would regardless are to systems a partner to Infrared conditions. our of be imaging Second, create with stimulation. useful where determining users lighting
this will than on we're based customized system. in to distant object. of filter to more identify partner with to accurately also users facial allow the patient objects their or easily developing integrated objects the a object auditory the and allow research de-cluttering the interest. distance. and/or stimulation defined focus depth where the Third, visual that vision a This located by Fourth, This out can we the In capabilities is that eliminates to artificial reach technology project with and from touch so allow users get distracting partner. with region develop grasp short, and excess information have to haptic vision possibly out would user objects further object a and a space provided additional system recognition highlights capabilities
looking Argus would hear another For that looking example, patient hear eventually at a the would phone, a or phone, Orion, word person's individual name. when or at using
developing As this a with see to technology is potential you vision. artificial we great know, rapidly integrate and
times the underway and several been evaluate to One calls that work vision continuing provided. stimulation to strategies is improve several various Finally, we has our acuity have internally. of effort new additional develop past and discussed efforts in the
experience. the during improve artificial still is this effort the vision no the increase these process. process reality and outcomes. could research assurance of the virtual in use are We in there's projects Another evaluation think rehab engagement rehab clear, technology To phase believe vision the usefulness of be and cases, complementary in provide, and usage moving early that commercialization. act we technology to development being quality artificial as improves some improve these the the many potential technologies have or or that user great With of or we significantly of said, in a to overall that
described the users as above benefit Argus would All of as Orion technologies well users.
priorities the our call speak Before over I'd turning like to John, to focus to moving forward. and
clinical as and Second and well confidence, continued size, top Orion will efforts market Orion for the R&D as priority the progress given First, our Sight. remain
in to are of necessary the us convinced the and is committed resources. technology We front with advancing Orion opportunity are a huge
given Argus market, to R&D We have RP maximum clinical we resources this efficiency decision Second, capital the commercial our apply made limited the faced to and maximize the activities. and given is the prudent challenges continued we in think need programs. with our Orion clinical to
allowing patients the of label efforts top field the without more for to centers Some bar vision a of and we deployment costly this expand include Argus markets resources the strategy business other continuation to In U.S. conducting financial potentially need implications Argus to short-term a markets of geographically. include be higher of trial. or excellence in strongest efficient U.S. of those focus increased and better RP to words, our new for IDE and our our convinced entering a payback markets on expanding
continue research will we the projects advancing exciting described earlier. Third,
the will our for hold see coworkers hard and results. goal now all now the John priority In talented ahead the and quarter stimulation moving huge evaluation. breakthrough development continued over the confidence incredible of research company our start in technologies, the Second promise and I'd treating like second that, my review since opportunity Orion blindness the company at the IPO. most We financial as the to of transform John? and the them support. the As Sight and to want to opportunity which been for closing, a progresses, with to I before toward turn the we grows cortical has clinical forms prioritize our materializes. to an technology thank for shareholders call With dedication market work the
